Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30‐day results
Open Access
- 15 November 2022
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 100 (7) , 1291-1299
Abstract
Background: Severe tricuspid regurgitation (TR) is independently associated with increased morbidity and mortality. Percutaneous transcatheter approaches may offer an alternative for patients not amenable to surgery.Methods: TriCLASP is a prospective, single‐arm, multicenter European post‐market clinical follow‐up study (NCT04614402) to evaluate the safety and performance of the PASCAL system (Edwards Lifesciences) in patients with severe or greater TR. At 30 days, a composite of major adverse events (MAEs) adjudicated by a clinical events committee, echocardiographic parameters adjudicated by core laboratory, and clinical, functional, and quality‐of‐life measures were evaluated.Results: Mean age of the 74 enrolled patients was 80.3 years, with 58.1% female, 90.5% systemic hypertension, and 77.0% in New York Heart Association (NYHA) class III/IV. Mean Society for Thoracic Surgeons score (MV repair) was 9.0%. TR severity was significantly reduced at discharge (p < 0.001) and sustained at 30 days (p < 0.001), and 90.0% of patients achieved ≤moderate TR. The composite MAE rate at 30 days was 3.0%, including 4 events in 2 patients: cardiovascular mortality 1.5%, stroke 1.5%, renal complications requiring unplanned dialysis or renal replacement therapy 1.5%, and severe bleeding 1.5%. There were no nonelective tricuspid valve reinterventions, major access site and vascular complications, major cardiac structural complications, or device embolizations. NYHA class I/II was achieved in 55.8%, 6‐minute walk distance improved by 38.2 m (p < 0.001), and Kansas City cardiomyopathy questionnaire scores improved by 13.4 points (p < 0.001).Conclusion: Experience with the PASCAL transcatheter valve repair system in a European post‐market setting confirms favorable safety and effectiveness at 30 days. TR significantly reduced, and clinical, functional, and quality‐of‐life outcomes significantly improved. This study is ongoing. Clinical Trial Registration: The study is ongoing and registered on ClinicalTrials.gov as NCT04614402. The current analysis is an interim report.Keywords
Funding Information
- Edwards Lifesciences
This publication has 16 references indexed in Scilit:
- Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection FractionCirculation, 2019
- Guidelines for the Evaluation of Valvular Regurgitation After Percutaneous Valve Repair or ReplacementJournal of the American Society of Echocardiography, 2019
- Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community SettingJACC: Cardiovascular Imaging, 2019
- Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysisEuropean Heart Journal, 2018
- Clinical Outcome of Isolated Tricuspid Regurgitation in Patients with Preserved Left Ventricular Ejection Fraction and Pulmonary HypertensionJournal of the American Society of Echocardiography, 2018
- National Trends and Outcomes in Isolated Tricuspid Valve SurgeryJACC, 2017
- The need for a new tricuspid regurgitation grading schemeEuropean Heart Journal - Cardiovascular Imaging, 2017
- Diagnosis and treatment of tricuspid valve disease: current and future perspectivesThe Lancet, 2016
- Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitionsEuropean Heart Journal, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingEuropean Heart Journal - Cardiovascular Imaging, 2015